Peptide aptamers: development and applications.

MIPs and Aptamers for Recognition of Proteins in Biomimetic Sensing. Biosensors (Basel) (2016) 0.87

Proteomic and Microscopic Strategies towards the Analysis of the Cytoskeletal Networks in Major Neuropsychiatric Disorders. Int J Mol Sci (2016) 0.75

Go in! Go out! Inducible control of nuclear localization. Curr Opin Chem Biol (2016) 0.75

Genetic Selection of Peptide Aptamers That Interact and Inhibit Both Small Protein B and Alternative Ribosome-Rescue Factor A of Aeromonas veronii C4. Front Microbiol (2016) 0.75

Synthetic biology for pharmaceutical drug discovery. Drug Des Devel Ther (2015) 0.75

Rapid Detection of Avian Influenza Virus by Fluorescent Diagnostic Assay using an Epitope-Derived Peptide. Theranostics (2017) 0.75

Targeting Inhibition of SmpB by Peptide Aptamer Attenuates the Virulence to Protect Zebrafish against Aeromonas veronii Infection. Front Microbiol (2017) 0.75

A novel genetic system to detect protein-protein interactions. Nature (1989) 43.83

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96

In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19

Man-made cell-like compartments for molecular evolution. Nat Biotechnol (1998) 11.44

Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science (1985) 10.42

Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04

Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 6.96

Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol (1997) 6.88

A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat Biotechnol (2002) 6.77

Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70

RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc Natl Acad Sci U S A (1997) 5.06

In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A (1997) 4.71

A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (N Y) (1993) 4.49

Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15

Thioredoxin--a fold for all reasons. Structure (1995) 3.85

Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67

Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol (2007) 3.56

Aptamers come of age - at last. Nat Rev Microbiol (2006) 3.33

Exploring protein fitness landscapes by directed evolution. Nat Rev Mol Cell Biol (2009) 3.13

Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol (2003) 2.81

A system for the continuous directed evolution of biomolecules. Nature (2011) 2.77

The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol (1998) 2.65

Antibody therapeutics in cancer. Science (2013) 2.64

Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat Biotechnol (1997) 2.54

An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci U S A (1994) 2.52

Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol (2009) 2.41

In vitro virus: bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro. FEBS Lett (1997) 2.40

Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature (1996) 2.34

Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol (1997) 2.21

Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol (2005) 1.99

Filamentous phage structure, infection and assembly. Curr Opin Struct Biol (1998) 1.96

Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol (2007) 1.93

Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev (2006) 1.92

A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol (2013) 1.85

Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett (2010) 1.85

Aptamers and their biological applications. Sensors (Basel) (2012) 1.76

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med (2010) 1.75

Site-specific antibody drug conjugates for cancer therapy. MAbs (2014) 1.74

Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods (2007) 1.68

Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J Mol Biol (2007) 1.67

Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2001) 1.64

Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol (2008) 1.64

DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol (2011) 1.61

Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol (2002) 1.57

Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol (2008) 1.57

Directed evolution of enzyme stability. Biomol Eng (2005) 1.56

Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res (2010) 1.51

Structural basis for ligand recognition and activation of RAGE. Structure (2010) 1.50

Nanobody-based products as research and diagnostic tools. Trends Biotechnol (2014) 1.50

Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol (2012) 1.50

An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel (2010) 1.48

Directed evolution of an extremely fast phosphotriesterase by in vitro compartmentalization. EMBO J (2003) 1.48

Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J (2008) 1.46

Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng Des Sel (2007) 1.46

Microbead display by in vitro compartmentalisation: selection for binding using flow cytometry. FEBS Lett (2002) 1.42

Optimizing non-natural protein function with directed evolution. Curr Opin Chem Biol (2010) 1.42

Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol (2007) 1.41

Diversity of phage-displayed libraries of peptides during panning and amplification. Molecules (2011) 1.41

RAGE: a single receptor fits multiple ligands. Trends Biochem Sci (2011) 1.39

Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res (2009) 1.38

Immobilizing proteins on the surface of yeast cells. Trends Biotechnol (1996) 1.38

Phage display screening without repetitious selection rounds. Anal Biochem (2011) 1.36

The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Anal Biochem (2005) 1.34

Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A (1999) 1.34

Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core. J Mol Biol (2007) 1.33

Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy. Mol Ther Nucleic Acids (2014) 1.32

Phage display: selecting straws instead of a needle from a haystack. Molecules (2011) 1.30

Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A (2006) 1.30

A new generation of protein display scaffolds for molecular recognition. Protein Sci (2006) 1.29

The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. EMBO J (1998) 1.27

Binding proteins from alternative scaffolds. J Immunol Methods (2004) 1.26

Two-hybrid technologies in proteomics research. Curr Opin Biotechnol (2008) 1.26

Biosynthesis and biological screening of a genetically encoded library based on the cyclotide MCoTI-I. Chembiochem (2009) 1.24

Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol (2005) 1.24

A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng (1995) 1.23

STABLE: protein-DNA fusion system for screening of combinatorial protein libraries in vitro. FEBS Lett (1999) 1.22

Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins. Curr Opin Pharmacol (2009) 1.21

Genetic immobilization of proteins on the yeast cell surface. Biotechnol Adv (2000) 1.21

T7 lytic phage-displayed peptide libraries exhibit less sequence bias than M13 filamentous phage-displayed peptide libraries. Proteomics (2006) 1.20

In vitro compartmentalization by double emulsions: sorting and gene enrichment by fluorescence activated cell sorting. Anal Biochem (2004) 1.20

Computational design of peptide ligands. Trends Biotechnol (2011) 1.19

A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination. Nat Struct Mol Biol (2010) 1.18

DARPins: a new generation of protein therapeutics. Drug Discov Today (2008) 1.17

Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J (2008) 1.17

An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc Natl Acad Sci U S A (1998) 1.15

A novel strategy to design binding molecules harnessing the modular nature of repeat proteins. FEBS Lett (2003) 1.15

Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel (2007) 1.13

Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface. Infect Immun (1997) 1.13

The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology (2008) 1.13

DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel (2007) 1.13

DNA display for in vitro selection of diverse peptide libraries. Nucleic Acids Res (2003) 1.12

Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. J Mol Biol (2008) 1.12

Diversity in genetic in vivo methods for protein-protein interaction studies: from the yeast two-hybrid system to the mammalian split-luciferase system. Microbiol Mol Biol Rev (2012) 1.11

RNA aptamers directed to discrete functional sites on a single protein structural domain. Proc Natl Acad Sci U S A (2007) 1.10

Experimental interrogation of the path dependence and stochasticity of protein evolution using phage-assisted continuous evolution. Proc Natl Acad Sci U S A (2013) 1.09

Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv (2013) 1.09

Constrained peptides as binding entities. Trends Biotechnol (1995) 1.09

Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel (2005) 1.08

Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84

Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem (2008) 1.51

Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem (2006) 1.40

Bicoid cooperative DNA binding is critical for embryonic patterning in Drosophila. Proc Natl Acad Sci U S A (2005) 1.36

Screening of small molecule interactor library by using in-cell NMR spectroscopy (SMILI-NMR). J Med Chem (2009) 1.05

Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem (2011) 1.04

The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry (2014) 1.02

Inhibition of biofilm formation, quorum sensing and infection in Pseudomonas aeruginosa by natural products-inspired organosulfur compounds. PLoS One (2012) 0.91

In-cell NMR spectroscopy. Prog Nucl Magn Reson Spectrosc (2010) 0.88

Structure of proteins in eukaryotic compartments. J Am Chem Soc (2012) 0.84

Fate of pup inside the Mycobacterium proteasome studied by in-cell NMR. PLoS One (2013) 0.83

Using singular value decomposition to characterize protein-protein interactions by in-cell NMR spectroscopy. Chembiochem (2014) 0.82

Combinatorial library of improved peptide aptamers, CLIPs to inhibit RAGE signal transduction in mammalian cells. PLoS One (2013) 0.81

Structural biology: Inside the living cell. Nature (2009) 0.81

Segmental labeling to study multidomain proteins. Adv Exp Med Biol (2012) 0.76